DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kumeria, Tushar | ko |
dc.contributor.author | Wang, Joanna | ko |
dc.contributor.author | Kim, Byungji | ko |
dc.contributor.author | Park, Ji-Ho | ko |
dc.contributor.author | Zuidema, Jonathan M. | ko |
dc.contributor.author | Klempner, Mark | ko |
dc.contributor.author | Cavacini, Lisa | ko |
dc.contributor.author | Wang, Yang | ko |
dc.contributor.author | Sailor, Michael J. | ko |
dc.date.accessioned | 2022-12-22T01:00:09Z | - |
dc.date.available | 2022-12-22T01:00:09Z | - |
dc.date.created | 2022-12-21 | - |
dc.date.created | 2022-12-21 | - |
dc.date.created | 2022-12-21 | - |
dc.date.created | 2022-12-21 | - |
dc.date.issued | 2022-10 | - |
dc.identifier.citation | ACS BIOMATERIALS SCIENCE & ENGINEERING, v.8, no.10, pp.4140 - 4152 | - |
dc.identifier.uri | http://hdl.handle.net/10203/303457 | - |
dc.description.abstract | Porous silicon (pSi) nanoparticles are loaded with Immunoglobulin A-2 (IgA2) antibodies, and the assembly is coated with pH-responsive polymers on the basis of the Eudragit family of enteric polymers (L100, S100, and L30-D55). The temporal release of the protein from the nanocomposite formulations is quantified following an in vitro protocol simulating oral delivery: incubation in simulated gastric fluid (SGF; at pH 1.2) for 2 h, followed by a fasting state simulated intestinal fluid (FasSIF; at pH 6.8) or phosphate buffer solution (PBS; at pH 7.4). The nanocomposite formulations display a negligible release in SGF, while more than 50% of the loaded IgA2 is released in solutions at a pH of 6.8 (FasSIF) or 7.4 (PBS). Between 21 and 44% of the released IgA2 retains its functional activity. A capsule-based system is also evaluated, where the IgA2-loaded particles are packed into a gelatin capsule and the capsule is coated with either EudragitL100 or EudragitS100 polymer for a targeted release in the small intestine or the colon, respectively. The capsule-based formulations outperform polymer-coated nanoparticles in vitro, preserving 45-54% of the activity of the released protein. © 2022 American Chemical Society. All rights reserved. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.title | Enteric Polymer-Coated Porous Silicon Nanoparticles for Site-Specific Oral Delivery of IgA Antibody | - |
dc.type | Article | - |
dc.identifier.wosid | 000867859400001 | - |
dc.identifier.scopusid | 2-s2.0-85097874875 | - |
dc.type.rims | ART | - |
dc.citation.volume | 8 | - |
dc.citation.issue | 10 | - |
dc.citation.beginningpage | 4140 | - |
dc.citation.endingpage | 4152 | - |
dc.citation.publicationname | ACS BIOMATERIALS SCIENCE & ENGINEERING | - |
dc.identifier.doi | 10.1021/acsbiomaterials.0c01313 | - |
dc.contributor.localauthor | Park, Ji-Ho | - |
dc.contributor.nonIdAuthor | Kumeria, Tushar | - |
dc.contributor.nonIdAuthor | Wang, Joanna | - |
dc.contributor.nonIdAuthor | Kim, Byungji | - |
dc.contributor.nonIdAuthor | Zuidema, Jonathan M. | - |
dc.contributor.nonIdAuthor | Klempner, Mark | - |
dc.contributor.nonIdAuthor | Cavacini, Lisa | - |
dc.contributor.nonIdAuthor | Wang, Yang | - |
dc.contributor.nonIdAuthor | Sailor, Michael J. | - |
dc.description.isOpenAccess | N | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordAuthor | biologic antibacterial therapeutics | - |
dc.subject.keywordAuthor | Eudragit polymer | - |
dc.subject.keywordAuthor | pH-responsive drug delivery | - |
dc.subject.keywordAuthor | oral drug delivery | - |
dc.subject.keywordPlus | ENHANCED PERMEABILITY | - |
dc.subject.keywordPlus | MONOCLONAL-ANTIBODY | - |
dc.subject.keywordPlus | CONTROLLED-RELEASE | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordPlus | PEPTIDE | - |
dc.subject.keywordPlus | INSULIN | - |
dc.subject.keywordPlus | NANO | - |
dc.subject.keywordPlus | MICROSPHERES | - |
dc.subject.keywordPlus | MICROPARTICLES | - |
dc.subject.keywordPlus | NANOCARRIERS | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.